PCVX Vaxcyte, Inc.
Stock · NasdaqGS · United States · Healthcare · US92243G1085
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Vaxcyte, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
63.89 USD
+3.18%
52-week range
40.14 – 90.75
Dividend yield—
Market cap10.1B
NowoTrade score
9 Grade C
Price history
Daily prices in USD.
Updated 07 Nov 2026 10:10. Information, not advice.
Results
Next results
23 Feb 2027
in 108 days · 16:00 · estimate -1.96
Last results
-1.99 vs -2.11 estimated
04 Nov 2026 · Beat +5.7%
Beat the estimate
4 of 12
8 missed · 0 in line · 2 beats in a row
Average surprise
-11.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 23 Feb 2027 16:00 | -1.96 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -2.11 | -1.99 | +5.7% | Beat |
| 05 Aug 2026 16:00 | -2.10 | -1.97 | +6.1% | Beat |
| 06 May 2026 16:00 | -1.77 | -2.30 | -29.7% | Miss |
| 24 Feb 2026 16:00 | -1.50 | -1.80 | -19.7% | Miss |
| 04 Nov 2025 16:00 | -1.24 | -1.56 | -26.3% | Miss |
| 06 Aug 2025 16:00 | -1.16 | -1.22 | -5.0% | Miss |
| 07 May 2025 16:00 | -0.97 | -1.04 | -6.7% | Miss |
| 25 Feb 2025 16:00 | -0.99 | -1.02 | -2.6% | Miss |
| 05 Nov 2024 16:00 | -0.99 | -0.83 | +16.1% | Beat |
| 06 Aug 2024 16:00 | -1.00 | -1.10 | -10.1% | Miss |
| 08 May 2024 16:00 | -1.06 | -0.85 | +20.1% | Beat |
| 27 Feb 2024 16:00 | -0.99 | -1.82 | -83.5% | Miss |
| 06 Nov 2023 16:00 | -0.84 | -0.91 | -8.8% | Miss |
| 08 Aug 2023 16:00 | -0.77 | -0.70 | +8.7% | Beat |
| 08 May 2023 16:00 | -0.88 | -0.70 | +20.2% | Beat |
| 27 Feb 2023 16:00 | -0.90 | -1.02 | -13.8% | Miss |
| 07 Nov 2022 16:00 | -0.85 | -0.93 | -8.8% | Miss |
| 08 Aug 2022 16:00 | -0.66 | -0.80 | -20.6% | Miss |
| 09 May 2022 16:00 | -0.66 | -0.68 | -3.0% | Miss |
| 28 Feb 2022 16:00 | -0.59 | -0.54 | +8.5% | Beat |
| 10 Nov 2021 16:00 | -0.58 | -0.51 | +12.8% | Beat |
| 11 Aug 2021 16:00 | -0.53 | -0.46 | +13.2% | Beat |
| 11 May 2021 16:00 | -0.56 | -0.41 | +26.8% | Beat |
| 29 Mar 2021 16:00 | -0.53 | -0.41 | +22.6% | Beat |
| 12 Nov 2020 16:00 | -0.44 | -0.41 | +7.5% | Beat |
| 12 Aug 2020 16:00 | -1.27 | -1.72 | -35.8% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -766.6M | — | -5.63 | -48.2% | -712.6M |
| 2024 | 0 | — | -463.9M | — | -3.80 | +8.2% | -571.8M |
| 2023 | 0 | — | -402.3M | — | -4.14 | -20.3% | -364.7M |
| 2022 | 0 | — | -223.5M | — | -3.44 | — | -176.4M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 61.92 | 65.30 | 61.14 | 63.89 | +3.18% | 1,840,900 | |
| 05 Nov 2026 | 65.88 | 65.88 | 61.84 | 61.92 | -5.72% | 1,833,800 | |
| 04 Nov 2026 | 62.87 | 65.71 | 60.04 | 65.68 | +8.01% | 2,257,700 | |
| 03 Nov 2026 | 61.38 | 61.89 | 60.32 | 60.81 | +0.31% | 2,176,600 | |
| 02 Nov 2026 | 61.88 | 62.87 | 60.15 | 60.62 | -2.27% | 1,320,400 | |
| 30 Oct 2026 | 62.59 | 63.28 | 61.02 | 62.03 | -0.93% | 1,714,300 | |
| 29 Oct 2026 | 61.88 | 63.14 | 61.64 | 62.61 | +1.87% | 2,013,800 | |
| 28 Oct 2026 | 59.92 | 63.94 | 59.58 | 61.46 | +1.30% | 2,212,600 | |
| 27 Oct 2026 | 59.92 | 61.30 | 59.43 | 60.67 | +1.17% | 2,587,400 | |
| 26 Oct 2026 | 60.68 | 61.50 | 59.19 | 59.97 | -0.76% | 1,469,400 | |
| 23 Oct 2026 | 62.35 | 62.77 | 60.27 | 60.43 | -3.85% | 2,062,400 | |
| 22 Oct 2026 | 62.96 | 64.58 | 61.56 | 62.85 | -0.60% | 2,771,300 | |
| 21 Oct 2026 | 66.02 | 67.46 | 63.09 | 63.23 | -4.53% | 3,272,200 | |
| 20 Oct 2026 | 63.80 | 67.01 | 63.68 | 66.23 | +4.00% | 1,956,700 | |
| 19 Oct 2026 | 64.14 | 66.02 | 63.38 | 63.68 | +0.09% | 2,549,200 | |
| 16 Oct 2026 | 65.13 | 65.34 | 62.54 | 63.62 | -2.53% | 3,249,900 | |
| 15 Oct 2026 | 67.72 | 68.33 | 65.00 | 65.27 | -3.38% | 2,448,500 | |
| 14 Oct 2026 | 67.07 | 69.21 | 66.00 | 67.55 | +1.12% | 1,525,200 | |
| 13 Oct 2026 | 70.58 | 71.09 | 66.63 | 66.80 | -5.45% | 2,644,900 | |
| 12 Oct 2026 | 71.08 | 72.89 | 68.97 | 70.65 | -1.02% | 2,427,600 | |
| 09 Oct 2026 | 64.78 | 72.44 | 64.78 | 71.38 | +9.79% | 4,381,400 | |
| 08 Oct 2026 | 67.14 | 67.97 | 63.79 | 65.01 | -2.90% | 3,848,100 | |
| 07 Oct 2026 | 65.86 | 67.15 | 64.27 | 66.96 | +0.39% | 11,561,100 | |
| 06 Oct 2026 | 73.35 | 73.39 | 63.90 | 66.70 | -9.65% | 10,156,100 | |
| 05 Oct 2026 | 87.21 | 90.75 | 71.60 | 73.82 | +30.70% | 14,924,000 |
Page 1 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update (opens in a new tab) 04 Nov 2026 21:05
- Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:30
- Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (opens in a new tab) Zacks · 30 Oct 2026 12:55
- Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet (opens in a new tab) Zacks · 14 Oct 2026 13:55
- Why Vaxcyte (PCVX) Is Getting Attention Again (opens in a new tab) Simply Wall St. · 08 Oct 2026 19:15
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers (opens in a new tab) Investor's Business Daily · 06 Oct 2026 21:34
- As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%) (opens in a new tab) TIKR · 06 Oct 2026 16:31
- Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results (opens in a new tab) Quartz · 06 Oct 2026 13:44
- Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial (opens in a new tab) MarketBeat · 06 Oct 2026 03:02
- NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test (opens in a new tab) Stocktwits · 06 Oct 2026 00:42
- Vaxcyte stock falls on $1B dual offering launch (opens in a new tab) Investing.com · 05 Oct 2026 22:26
- PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case (opens in a new tab) Stocktwits · 05 Oct 2026 19:37
- Nvidia, Intel, Micron, XP Inc., PTC, Vaxcyte, Western Digital, and More Stocks That Explain Today’s Market (opens in a new tab) Barrons.com · 05 Oct 2026 19:31
- Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck (opens in a new tab) Barrons.com · 05 Oct 2026 17:52
- 🔎 Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds Up in Study (opens in a new tab) The Wall Street Journal · 05 Oct 2026 17:48
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 61.92 USD
- Market cap
- 10.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -8.98× | Weak | 14.98× |
| Price / book | 3.12× | Weak | 3.94× |
| EV / EBITDA | -7.31× | Weak | 12.96× |
| Free cash flow yield | -4.8% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 59.2% |
| Operating margin | 0% | Weak | 7.4% |
| Net margin | 0% | Weak | 3.4% |
| Return on equity | -36.5% | Weak | 5.7% |
| Return on assets | -22.6% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.04× | Good | 0.46× |
| Current ratio | 5.72× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow PCVX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.